Posts

AZ wins EU nod for camizestrant

on

Celcuity shares fall as delayed breast cancer drug launch eclipses first US FDA approval

on

Celcuity Wins FDA Approval for First-in-Class Breast Cancer Drug Revtorpyk (gedatolisib)

on

Genentech lays off 103 as part of gRED rethink, advances with $490M breast cancer collaboration

on

ASCO26: AstraZeneca unveils data it hopes will persuade FDA to approve oral SERD

on

KOL Insight: HR‑Positive/HER2‑Negative Breast Cancer (June 1, 2026)

on

FDA delays camizestrant breast cancer drug decision after ODAC vote against benefit-risk profile

on

FDA Grants Daiichi Sankyo and AstraZeneca’s Datroway a Key Breast Cancer Approval

on

AstraZeneca Wins EU Backing for Breast Cancer Drug, Splitting With FDA Panel

on

Rigel Pharmaceuticals Secures Licensing Deal for Arvinas and Pfizer's FDA-Approved Breast Cancer Drug VEPPANU

on

Caris Life Sciences Launches Caris MI Clarity: AI-Powered Test for Breast Cancer Recurrence Risk Prediction

on

Celcuity's Gedatolisib Achieves Phase 3 Success in PIK3CA-Mutant Breast Cancer as FDA Decision on Wild-Type NDA Nears

on

FDA Approves Arvinas and Pfizer's Veppanu (vepdegestrant), First PROTAC for ESR1-Mutated Breast Cancer

on

Biopharma Bites: AstraZeneca's Camizestrant Faces FDA ODAC Scrutiny Amid Trial Design Concerns

on

FDA's Oncologic Drugs Advisory Committee to Review AstraZeneca's Cancer Drugs in First Meeting in 9 Months

on

Roche's Oral SERD Giredestrant Shows Mixed Clinical Results but Remains Strategically Important

on

Prelude Therapeutics Presents Preclinical Data on PRT13722 KAT6A Degrader at AACR 2026

on

Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update

on

Novartis Pays Synnovation $2B Upfront for Breast Cancer Drug SNV4818 as Rivals Compete

on

Roche's Oral SERD Giredestrant Fails Phase 3 persevERA Trial in First-Line Breast Cancer

on